Compass Pathways plc (CMPS) is a clinical-stage biopharmaceutical company developing psychedelic-assisted therapies for mental health disorders. The analysis reveals non-compliance primarily due to a high liquidity ratio exceeding Shariah thresholds across major standards, despite low debt and no non-permissible income. Business activities are generally permissible, but the pre-revenue stage and high cash holdings pose challenges. No inclusion in major Shariah indices confirms the non-compliant status. Investors should monitor for improvements in asset utilization and consult scholars on psychedelic therapies.